Loading...
Loading...
CELC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 22.5M |
| Operating I/L | -22.5M |
| Other Income/Expense | 0.9M |
| Interest Income | 2.3M |
| Pretax | -21.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -21.6M |
Celcuity Inc. is a clinical stage biotechnology company specializing in the development of molecularly targeted therapies for cancer patients. The company's CELsignia diagnostic platform utilizes living tumor cells to identify specific abnormal cellular processes driving a patient's cancer and the related targeted therapy for treatment. Its drug candidate, Gedatolisib, targets various class I isoforms of PI3K and mammalian target of rapamycin, focusing on treating patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. Additionally, Celcuity Inc. is developing the CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.
